AISA Pharma Announces Start of Phase 2b Profervia® Study for Raynaud's Phenomenon in Systemic Sclerosis (SSc)

Aisa Pharma has initiated the second part of its RECONNOITER Phase 2 study, which will evaluate Profervia®, an oral calcium-channel antagonist, in patients with systemic sclerosis and Raynaud's phenomenon. The double-blind, placebo-controlled, randomized, prospective crossover study is expected to last approximately 10 months. Aisa also presented positive safety and efficacy data from the Phase ..